Phase II Study of S-1 plus Cisplatin as First-Line Therapy in Patients with Metastatic Esophageal Carcinoma

Oncology Research and Treatment
Si SunJianhua Chang

Abstract

Patients with metastatic esophageal squamous cell cancer (ESCC) need safer and more efficacious treatments. The aim of this phase II study was to investigate the efficacy and safety of S-1 plus cisplatin as first-line therapy in metastatic ESCC. 50 patients with metastatic ESCC who had not received prior systemic chemotherapy for metastatic disease were enrolled. Patients received S-1 at 40 mg/m2 divided into 2 daily doses for 14 days and cisplatin at 75 mg/m2 on day 1 or 25 mg/m2 on days 1-3 intravenously, repeated every 21 days with a maximum of 6 cycles. 47 patients were assessable for response and 18 patients achieved a partial response, giving an overall response rate of 38.3%. Among those who had objective responses, a large percentage (72.2%) quickly showed remarkable tumor shrinkage during the first 2 cycles. 18 (38.3%) patients had stable disease. The median progression-free survival was 5.6 months, and the median overall survival was 12.0 months. Toxicity was mild to moderate and generally tolerable. The combination of S-1 plus cisplatin was a well-tolerated and convenient chemotherapy regimen with promising efficacy.

References

Jul 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H BleibergT Sahmoud
Oct 3, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D H IlsonD P Kelsen
May 9, 2000·Journal of the American College of Surgeons·J M DalyA M Fremgen
May 28, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A M MauerE E Vokes
Sep 15, 2005·International Journal of Cancer. Journal International Du Cancer·Mitsuhiko HanawaAkishi Ooi
Apr 1, 2008·American Journal of Clinical Oncology·Xiaodong ZhangMaolin Jin
Feb 18, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jaffer A AjaniSilvia Falcon
Feb 5, 2013·Lancet·Arjun PennathurJames D Luketich
Jul 3, 2013·CA: a Cancer Journal for Clinicians·Jesper Lagergren, Pernilla Lagergren
May 17, 2014·World Journal of Gastrointestinal Oncology·Kyle J NapierSubhasis Misra
Jul 18, 2014·Expert Opinion on Pharmacotherapy·Yuji MiyamotoHideo Baba
Nov 12, 2014·World Journal of Gastroenterology : WJG·Kentaro SudoTaketo Yamaguchi
Dec 30, 2014·The New England Journal of Medicine·Anil K Rustgi, Hashem B El-Serag
Mar 17, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Jing HuangYan Sun

❮ Previous
Next ❯

Citations

Sep 25, 2021·Updates in Surgery·Takamasa TakahashiKazuaki Seita

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.